Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC.ALNY · Entity 3132 | Director | July 01, 2019 | July 02, 2019 |
| Forte Biosciences, Inc.TOCA · Entity 9529 | Director | October 04, 2019 | October 05, 2019 |
| aTYR PHARMA INCATYR · Entity 7233 | Director | May 27, 2026 | May 28, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALNYLAM PHARMACEUTICALS, INC.
Report date July 01, 2019 · Filed July 02, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $72.01 · Expires 2029-06-30 | Direct | 9,000 |
Reported balance
After 2019-07-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-07-01 · Grant · Acquired 9,000 · Balance 9,000 |
Forte Biosciences, Inc.
Report date October 04, 2019 · Filed October 05, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.64 · Expires 2029-10-03 | Direct | 7,500 |
Reported balance
After 2019-10-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-10-04 · Grant · Acquired 7,500 · Balance 7,500 F1: The shares vest in a series of twelve (12) successive equal monthly installments measured from October 3, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares vest in a series of twelve (12) successive equal monthly installments measured from October 3, 2019.
aTYR PHARMA INC
Report date May 27, 2026 · Filed May 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 779,143 |
Reported balance
After 2026-05-27 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2026-05-27 · Purchase · Acquired 100,000 · Balance 779,143 F1: Represents weighted average price for the shares. The shares were purchased at prices ranging from $0.4907 to $0.50 per share. The Reporting Person will provide to the Securities and Exchange Commission staff, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares purchased at each separate price. F2: These shares are owned directly by Schimmel Revocable Trust U/A Dtd 9/6/2000. The Reporting Person and his spouse are trustees of the Schimmel Revocable Trust U/A Dtd 9/6/2000. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 1,413,023 |
Reported balance
Holding disclosure · report date 2026-05-27 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 1,413,023 F3: These shares are owned directly by Paul Schimmel Prototype PSP, Paul Schimmel Trustee, FBO Paul Schimmel. The Reporting Person is the sole owner of the Paul Schimmel Prototype PSP, Paul Schimmel Trustee, FBO Paul Schimmel. |
| Common StockSEC Table I · non-derivative | Direct | 8,890 |
Reported balance
Holding disclosure · report date 2026-05-27 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 8,890 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents weighted average price for the shares. The shares were purchased at prices ranging from $0.4907 to $0.50 per share. The Reporting Person will provide to the Securities and Exchange Commission staff, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares purchased at each separate price.
F2: These shares are owned directly by Schimmel Revocable Trust U/A Dtd 9/6/2000. The Reporting Person and his spouse are trustees of the Schimmel Revocable Trust U/A Dtd 9/6/2000.
F3: These shares are owned directly by Paul Schimmel Prototype PSP, Paul Schimmel Trustee, FBO Paul Schimmel. The Reporting Person is the sole owner of the Paul Schimmel Prototype PSP, Paul Schimmel Trustee, FBO Paul Schimmel.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 19, 2017 Filed Apr 21, 2017 21:34 UTC | Forte Biosciences, Inc. TOCA · Entity 9529 | ConversionSeries H Preferred Stock · Derivative | 161,906 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-027905 · doc4.xml · derivative · entry 6 SCHIMMEL PAUL · CIK 0001236447 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 23,464 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Automatic conversion, in connection with the Issuer's initial public offering, of preferred stock into shares of common stock on a 1-for-6.9 basis. The shares have no expiration date. F1 · derivative.exercise_date: Automatic conversion, in connection with the Issuer's initial public offering, of preferred stock into shares of common stock on a 1-for-6.9 basis. The shares have no expiration date. F1 · derivative.expiration_date: Automatic conversion, in connection with the Issuer's initial public offering, of preferred stock into shares of common stock on a 1-for-6.9 basis. The shares have no expiration date. Read SEC document |
| April 19, 2017 Filed Apr 21, 2017 21:34 UTC | Forte Biosciences, Inc. TOCA · Entity 9529 | PurchaseCommon Stock | 10,000 | $10.00 | $100,000.00 |
DisclosureSEC source: 0001209191-17-027905 · doc4.xml · nonDerivative · entry 5 SCHIMMEL PAUL · CIK 0001236447 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Schimmel Revocable Trust Paul R. Schimmel, Trustee Cleo Schimmel, Trustee U/A dtd 9/6/2000 Disclosed balance after: 13,623 F2 · kind: The shares were purchased at the Issuer's initial public offering. Read SEC document |
| April 19, 2017 Filed Apr 21, 2017 21:34 UTC | Forte Biosciences, Inc. TOCA · Entity 9529 | ConversionCommon Stock | 3,623 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-027905 · doc4.xml · nonDerivative · entry 4 SCHIMMEL PAUL · CIK 0001236447 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Schimmel Revocable Trust Paul R. Schimmel, Trustee Cleo Schimmel, Trustee U/A dtd 9/6/2000 Disclosed balance after: 3,623 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Automatic conversion, in connection with the Issuer's initial public offering, of preferred stock into shares of common stock on a 1-for-6.9 basis. The shares have no expiration date. Read SEC document |
| April 19, 2017 Filed Apr 21, 2017 21:34 UTC | Forte Biosciences, Inc. TOCA · Entity 9529 | ConversionCommon Stock | 3,623 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-027905 · doc4.xml · nonDerivative · entry 3 SCHIMMEL PAUL · CIK 0001236447 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Paul Schimmel Prototype PSP Paul R. Schimmel, TTEE U/A dtd 01/01/1999 FBO Paul Schimmel Disclosed balance after: 3,623 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Automatic conversion, in connection with the Issuer's initial public offering, of preferred stock into shares of common stock on a 1-for-6.9 basis. The shares have no expiration date. Read SEC document |
| April 19, 2017 Filed Apr 21, 2017 21:34 UTC | Forte Biosciences, Inc. TOCA · Entity 9529 | ConversionCommon Stock | 4,117 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-027905 · doc4.xml · nonDerivative · entry 2 SCHIMMEL PAUL · CIK 0001236447 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By NFS/FMTC FBO Paul Schimmel Rollover IRA Disclosed balance after: 4,117 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Automatic conversion, in connection with the Issuer's initial public offering, of preferred stock into shares of common stock on a 1-for-6.9 basis. The shares have no expiration date. Read SEC document |
| April 19, 2017 Filed Apr 21, 2017 21:34 UTC | Forte Biosciences, Inc. TOCA · Entity 9529 | ConversionCommon Stock | 23,464 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-027905 · doc4.xml · nonDerivative · entry 1 SCHIMMEL PAUL · CIK 0001236447 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,464 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Automatic conversion, in connection with the Issuer's initial public offering, of preferred stock into shares of common stock on a 1-for-6.9 basis. The shares have no expiration date. Read SEC document |
| April 12, 2017 Filed Apr 13, 2017 01:09 UTC | Forte Biosciences, Inc. TOCA · Entity 9529 | GrantStock Option (right to buy) · Derivative | 4,528 | $0.00 Strike: $10.00 | $0.00 |
DisclosureSEC source: 0001209191-17-026757 · doc4.xml · derivative · entry 1 SCHIMMEL PAUL · CIK 0001236447 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,528 Underlying: Common Stock · 4,528 shares Expires 2027-04-11 F1 · derivative.exercise_date: 1/4th of the shares vest one year after 4/1/2017; the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of 4/1/2017. Read SEC document |
| December 21, 2016 Filed Dec 22, 2016 16:53 UTC | aTYR PHARMA INC LIFE · Entity 7233 | PurchaseCommon Stock | 10,000 | $2.28 | $22,818.00 |
DisclosureSEC source: 0001209191-16-156424 · doc4.xml · nonDerivative · entry 3 SCHIMMEL PAUL · CIK 0001236447 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 721,814 F1 · ownership.nature: These shares are owned directly by Schimmel Revocable Trust U/A Dtd 9/6/2000. The Reporting Person and his spouse are trustees of the Schimmel Revocable Trust U/A Dtd 9/6/20. Read SEC document |
| December 20, 2016 Filed Dec 22, 2016 16:53 UTC | aTYR PHARMA INC LIFE · Entity 7233 | PurchaseCommon Stock | 15,000 | $2.27 | $34,110.00 |
DisclosureSEC source: 0001209191-16-156424 · doc4.xml · nonDerivative · entry 2 SCHIMMEL PAUL · CIK 0001236447 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 711,814 F1 · ownership.nature: These shares are owned directly by Schimmel Revocable Trust U/A Dtd 9/6/2000. The Reporting Person and his spouse are trustees of the Schimmel Revocable Trust U/A Dtd 9/6/20. Read SEC document |
| December 16, 2016 Filed Dec 20, 2016 00:41 UTC | aTYR PHARMA INC LIFE · Entity 7233 | PurchaseCommon Stock | 10,000 | $2.40 | $23,973.00 |
DisclosureSEC source: 0001209191-16-156022 · doc4.xml · nonDerivative · entry 4 SCHIMMEL PAUL · CIK 0001236447 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 696,814 F1 · ownership.nature: There shares are owned directly by Schimmel Revocable Trust U/A Dtd 9/6/2000. The Reporting Person and his spouse are trustees of the Schimmel Revocable Trust U/A Dtd 9/6/2000. Read SEC document |
| December 15, 2016 Filed Dec 20, 2016 00:41 UTC | aTYR PHARMA INC LIFE · Entity 7233 | PurchaseCommon Stock | 40,000 | $2.50 | $99,912.00 |
DisclosureSEC source: 0001209191-16-156022 · doc4.xml · nonDerivative · entry 3 SCHIMMEL PAUL · CIK 0001236447 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 686,814 F2 · price: Represents weighted price for the shares. The shares were purchased at prices ranging from $2.3469 to $2.6411 per share. The reporting person will provide to the Securities and Exchange Commission staff, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares purchased at each separate price. F1 · ownership.nature: There shares are owned directly by Schimmel Revocable Trust U/A Dtd 9/6/2000. The Reporting Person and his spouse are trustees of the Schimmel Revocable Trust U/A Dtd 9/6/2000. Read SEC document |
| September 23, 2016 Filed Dec 20, 2016 00:41 UTC | aTYR PHARMA INC LIFE · Entity 7233 | GiftCommon Stock | 12,572 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-156022 · doc4.xml · nonDerivative · entry 2 SCHIMMEL PAUL · CIK 0001236447 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 646,814 F1 · ownership.nature: There shares are owned directly by Schimmel Revocable Trust U/A Dtd 9/6/2000. The Reporting Person and his spouse are trustees of the Schimmel Revocable Trust U/A Dtd 9/6/2000. Read SEC document |
| September 23, 2016 Filed Dec 20, 2016 00:41 UTC | aTYR PHARMA INC LIFE · Entity 7233 | GiftCommon Stock | 12,572 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-156022 · doc4.xml · nonDerivative · entry 1 SCHIMMEL PAUL · CIK 0001236447 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,440 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.